MARKETS & MATERIALS
Data & sources →

Nasdaq · dated source prices · weekly rankings in the Weekly 250

THE GLOBAL FINANCIAL WEEKLYNovember 9–15, 2026Vol. 01 · No. 005
News / All topics / IPO's

TOPIC NEWS · November 9–15, 2026

IPO's

A clinical-stage biotechnology offering illustrates why the public share sale, strategic financing and closing timetable must be read separately.

IPO's

Expected gross proceeds before fees

USD million; public amount rounded

087.5175175Public IPO50Private placement
November 12 pricing; expected November 16 closing remains prospective. [1]

Sources: [1] Windward Bio: pricing announcement filed under Rule 433 · 2026-11-12; closing expected November 16, after cutoff

Windward Prices Its IPO Alongside a Private Placement

A clinical-stage biotechnology offering illustrates why the public share sale, strategic financing and closing timetable must be read separately.

Sources: Windward Bio: pricing announcement filed under Rule 433; SEC Investor.gov: Updated Investor Bulletin, Investing in an IPO

Read the report →

IPO's PREMIUM

Expected gross proceeds before fees

USD million; public amount rounded

087.5175175Public IPO50Private placement
November 12 pricing; expected November 16 closing remains prospective. [1]

Sources: [1] Windward Bio: pricing announcement filed under Rule 433 · 2026-11-12; closing expected November 16, after cutoff

Read the financing in separate layers

A clinical-stage biotechnology offering illustrates why the public share sale, strategic financing and closing timetable must be read separately.

Sources: Windward Bio: pricing announcement filed under Rule 433; SEC Investor.gov: Updated Investor Bulletin, Investing in an IPO

Read premium analysis →